by The global viral vectors & plasmid DNA manufacturing market size reached USD 6.26 billion in 2024 and is expected to be cross around USD 26.66 billion by 2034 with a CAGR of 15.59%.
Get Sample Copy of Report@ https://www.precedenceresearch.com/sample/1012
Key Takeaways
- North America dominated the market in 2024, accounting for 49% of the total revenue share.
- The AAV segment exhibited significant growth in the vector type category, holding a 21% share in 2024.
- The downstream processing segment was the most prominent in workflow, securing a 54% revenue share in 2023.
- The vaccinology segment led the market by application, contributing around 22.5% of the revenue in 2024.
- Cancer was the most dominant disease category, generating 38% of the total market revenue in 2024.
- Research institutes accounted for the largest end-use share, capturing approximately 58.4% of the market revenue in 2024.
Market Overview
The viral vectors and plasmid DNA manufacturing market is expanding rapidly, driven by the increasing demand for gene therapy, cell therapy, and vaccine development. These genetic materials play a crucial role in biotechnology, enabling advancements in treating genetic disorders, cancers, and infectious diseases. The rising prevalence of chronic diseases and growing investments in biopharmaceutical research further fuel market growth.
Drivers
Key drivers of the market include the rising adoption of gene and cell therapies, which require efficient viral vector production. The demand for advanced therapeutics in treating genetic disorders and cancer is increasing, pushing the need for large-scale manufacturing. Additionally, technological innovations in bioprocessing techniques enhance production efficiency and scalability.
Opportunities
The growing focus on personalized medicine presents significant opportunities for the market. Expansion in biopharmaceutical research and collaborations between biotech firms and research institutions are expected to drive innovation. Emerging markets also offer lucrative prospects as governments and private players invest in healthcare infrastructure and advanced treatment solutions.
Challenges
High production costs and complexities in large-scale manufacturing remain major challenges. Regulatory hurdles and stringent quality control requirements add to the complexity of bringing new therapies to market. Additionally, the limited availability of skilled professionals in the biotechnology sector can slow down advancements.
Regional Insights
North America leads the market due to strong R&D investments and a well-established biotech industry. Europe follows closely, driven by increasing clinical trials and regulatory support for gene therapies. The Asia-Pacific region is witnessing rapid growth, fueled by rising healthcare expenditures, government initiatives, and an increasing number of biopharma companies.
Viral Vectors & Plasmid DNA Manufacturing Market Companies
- Novasep
- Aldevron
- MerckWaismanBiomanufacturing
- Creative Biogene
- The Cell and Gene Therapy Catapult
- Cobra Biologics
- uniQure N.V.
- Addgene
- FUJIFILM Holdings Corporation
- Oxford Biomedicaplc
- Takara Bio Inc.
Recent Developments
- In May 2024, Charles River Laboratories International, Inc. declared the starting of its Modular and Fast Track viral vector technology transfer frameworks.
- In November 2023, SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization, has recently started two new viral vector platforms expected to save time and cost in manufacturing innovative cell and gene therapies (CGTs).
- In February 2023, ProBio and RVAC Medicines Pte. Ltd. declared an agreement to establish a strategic partnership to produce GMP-grade plasmid DNA (pDNA) for its mRNA COVID-19 vaccine candidate, RVM-V001, along with collaboration for future therapeutic pipelines.
Market Segmentation
This research report estimates revenue growth at global, regional, and country levels and offers an analysis of present industry trends in everysub-segment from 2025 to 2034. This research study analyzes market thoroughly by classifying global viral vectors & plasmid DNA manufacturing market report on the basis of different parameters including type of vector, application, workflow, end users, disease, and region:
By Vector Type
- Adenovirus
- Plasmid DNA
- Lentivirus
- Retrovirus
- AAV
- Others
By Application
- Gene Therapy
- Antisense &RNAi
- Cell Therapy
- Vaccinology
By Workflow
- Upstream Processing
- Vector Recovery/Harvesting
- Vector Amplification & Expansion
- Downstream Processing
- Fill-finish
- Purification
By End-User
- Biopharmaceutical and Pharmaceutical Companies
- Research Institutes
By Disease
- Genetic Disorders
- Cancer
- Infectious Diseases
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of the World
Ready for more? Dive into the full experience on our website@ https://www.precedenceresearch.com/
- Transplantation Market Size To Surge USD 39.19 Bn By 2034 - March 4, 2025
- N95 Medical Protective Masks Market Size to Soar USD 8.25 billion by 2034 - March 4, 2025
- Disposable Endoscopes Market Size to Hit USD 10.82 Bn by 2034 - March 3, 2025
